Table 3.
Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of screening algorithms for end-stage renal disease (ESRD) and end-stage liver disease (ESLD) outcomes among participants in the randomly selected subcohort (n = 2,415 for ESRD and n = 2,422 for ESLD).
| Outcome | Screened positive (n) | Verified case (n) | Sensitivity | Specificity | PPV | NPV |
|---|---|---|---|---|---|---|
| End-stage renal disease | ||||||
| Overall (diagnosis OR laboratory) | 76 | 62 | 100% | 99% | 82% | 100% |
| Diagnosis criteria only | 21 | 17 | 27% | 100% | 81% | 98% |
| Laboratory criteria only | 58 | 48 | 77% | 100% | 83% | 99% |
| Diagnosis AND laboratory criteria | 3 | 3 | 5% | 100% | 100% | 98% |
| End-stage liver disease | ||||||
| Overall (diagnosis OR laboratory) | 154 | 41 | 100% | 95% | 27% | 100% |
| Diagnosis criteria only | 135 | 39 | 95% | 96% | 29% | 100% |
| Laboratory criteria only | 36 | 8 | 20% | 99% | 22% | 99% |
| Diagnosis AND laboratory criteria | 17 | 6 | 15% | 100% | 35% | 99% |
| Diagnosis of ascites, SBP, or variceal hemorrhagea | 62 | 24 | 59% | 98% | 39% | 99% |
aSubgroup of diagnoses used to screen for ESLD.